Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients

European Journal of Medical Research

Volumn 10, Issue 4, 2005, Pages 161-168

  Böger, Carsten A ^a   Gotz A K ^a   Kruger B ^a   Hosl M ^a   Schmitz, G ^a   Riegger, G A J ^a   Kramer B K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Diabetes mellitus; Dialysis; Genetics; Hypertension; Nephropharmacology; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; VALSARTAN;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE ASSOCIATION; DRUG INDICATION; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART VENTRICLE FUNCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PHARMACOGENETICS; QUESTIONNAIRE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; WILD TYPE;

AGED; ALLELES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; BLOOD PRESSURE; CHRONIC DISEASE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 17844410684     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. US Renal Data System: Excerpts from the USRDS 1999 Annual Data Report (1999). Am J Kidney Dis 34(Suppl 1): S74-S86
2. Ganesh SK, Hulbert-Shearon T, Port FK, et al. (2003). Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol, 14: 415-24
3. Parfrey PS, Foley RN (1999). The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 1606-15
4. Kannel WB, McGee D (1979). Diabetes and cardiovascular risk factors in the Framingham study. Circulation 59: 8-13
5. Lindholm LH, Ibsen H, Dahlof B, et al.; LIFE Study Group (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004-10
6. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-9
7. Yusuf S, Sleight P, Pogue J, et al. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-53
8. The Hope Investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253-9
9. Svensson P; de Faire U; Sleight P, et al. (2001). Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38: E28-32
10. MacMahon S; Sharpe N; Gamble G; Clague A; Mhurchu CN; Clark T; Hart H; Scott J; White H (2000). Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 36: 438-43
11. The PEACE investigators (2004). Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. N Engl J Med 351: 2058-68
12. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM (2001). Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987-92
13. Foley RN, Herzog CA, Collins AJ (2002). Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62: 1784-90
14. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C (2002). Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 61: 2157-64
15. Chow FYF, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG (2003). Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology 8: 177-83
16. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh A, Weissgarten J (2002). ACE inhibitors and survival of hemodialyis patients. Am J Kidney Dis 40: 1023-9
17. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC (2003). Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139: 105-12
18. Berger AK, Duval S, Krumholz HM (2003). Aspirin, betablocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42:201-8
19. Schwartz GL, Turner ST (2004). Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 4: 151-60
20. Risch NJ (2000). Searching for genetic determinants in the new millenium. Nature 405: 847-56
21. Rigat B, Hubert C, Alhenic-Gelas F, et al. (1990). An insertion/deletion polymorphism in the angiotensin-I-converting enzyme accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-6
22. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjaerg-Hansen A (2001). Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study. Hypertension 37: 875-81
23. Hingorani AD, Jia H, Stevens PA, et al. (1995). Renin-angiotensin system gene polymorphisms influence blood pressure and response to angiotensin converting enzyme inhibition. J Hyperten 13: 1602-9
24. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F (1994). Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24: 63-9
25. Benetos A, Cambien F, Gautier S, et al. (1996). Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 28: 1081-4
26. Böger CA, Götz A, Stubanus M, et al.. C-reactive protein as predictor of death in end stage diabetic nephropathy: role of peripheral arterial disease. Kidney International (in press)
27. Dupont WD, Plummer WD Jr (1990). PS power and sample size calculations. A review and computer program. Controlled Clin Trials 11: 116-28
28. Flather MD; Yusuf S; Kober L; Pfeffer M; Hall A; Murray G; Torp-Pedersen C; Ball S; Pogue J; Moye L; Braunwald E (2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575-81
29. Konstam MA; Kronenberg MW; Rousseau MF; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D; et al. (1993). Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 88: 2277-83
30. Miki T; Miura T; Tsuchida A; Nakano A; Hasegawa T; Fukuma T; Shimamoto K (2000). Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation 102: 458-63
31. Mancini GB; Henry GC; Macaya C; O'Neill BJ; Pucillo AL; Carere RG; Wargovich TJ; Mudra H; Luscher TF; Klibaner MI; Haber HE; Uprichard AC; Pepine CJ; Pitt B (1996). Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94: 258-65
32. Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ (2003). Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 107: 579-85
33. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T (2004). Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 27: 1712-5
34. Soejima H; Ogawa H; Yasue H; Kaikita K; Takazoe K; Nishiyama K; Misumi K; Miyamoto S; Yoshimura M; Kugiyama K; Nakamura S; Tsuji I (1999). Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 34: 983-8
35. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. (2002). The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538
36. Miyazaki H, Matsuko H, Itabe H et al. (2000). Hemodialysis impairs endothelial function via oxidative stress. Circulation 101: 1002-1006
37. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W (2003). Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290: 353-9
38. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA, Murali S, Rosenblum WD, London B, Feldman AM (2001). Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103: 1644-8
39. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, Murali S, Feldman AM, London B (2004). Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 44: 2019-26
40. Grimes DA, Schulz KF (2002). Bias and causal associations in observational research. Lancet 359: 248-52